ANS02 Phase 1 Study for EGFR Mutation-Positive NSCLC

NIH registered a new first-in-human Phase 1/II clinical trial (NCT07538804) for ANS02, an investigational drug for EGFR mutation-positive non-small cell lung cancer. The study is multi-center, open-label, and will evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, and anti-tumor activity as monotherapy. The trial is listed as Phase 1 with a status date of April 20, 2026.

For pharmaceutical companies and clinical research organizations, this registration demonstrates the continued use of ClinicalTrials.gov as the primary public registry for U.S. clinical trials, supporting transparency obligations under FDA regulations. Sponsors conducting similar oncology trials should ensure their studies are properly registered and updated in accordance with applicable disclosure requirements.